Cargando…

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

In the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death, and increased eligibility for treatment-free r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kantarjian, Hagop M., Hughes, Timothy P., Larson, Richard A., Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Boquimpani, Carla, Pasquini, Ricardo, Clark, Richard E., Dubruille, Viviane, Flinn, Ian W., Kyrcz-Krzemien, Slawomira, Medras, Ewa, Zanichelli, Maria, Bendit, Israel, Cacciatore, Silvia, Titorenko, Ksenia, Aimone, Paola, Saglio, Giuseppe, Hochhaus, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862065/ https://www.ncbi.nlm.nih.gov/pubmed/33414482 http://dx.doi.org/10.1038/s41375-020-01111-2

Ejemplares similares

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
por: Hochhaus, A, et al.
Publicado: (2016)

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
por: Radich, Jerald P., et al.
Publicado: (2021)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
por: Hochhaus, A, et al.
Publicado: (2017)

Suboptimal Responses in Chronic Myeloid Leukemia
por: Jabbour, Elias, et al.
Publicado: (2012)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
por: Hochhaus, A, et al.
Publicado: (2016)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
por: Ross, David M., et al.
Publicado: (2018)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
por: Schönfeld, Lioba, et al.
Publicado: (2022)

Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034
por: Shah, Neil P., et al.
Publicado: (2016)

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
por: Stein, Andrew M, et al.
Publicado: (2013)

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis
por: Giles, Francis J., et al.
Publicado: (2017)

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells
por: Drube, Julia, et al.
Publicado: (2018)

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis
por: Hochhaus, Andreas, et al.
Publicado: (2017)

Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study
por: Conchon, Monika, et al.
Publicado: (2009)

Coexistence of Chronic Lymphocytic Leukemia and Myeloproliferative Neoplasm
por: Zielinska, Patrycja, et al.
Publicado: (2014)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
por: Alqasim, Alauldeen Mudhafar Zubair, et al.
Publicado: (2018)

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
por: Gullaksen, Stein-Erik, et al.
Publicado: (2017)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
por: Al-Jafar, Hassan A., et al.
Publicado: (2015)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
por: Steegmann, Juan Luis, et al.
Publicado: (2017)

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
por: Hochhaus, Andreas, et al.
Publicado: (2023)

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia
por: Galimberti, Sara, et al.
Publicado: (2017)

Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
por: Steegmann, Juan Luis, et al.
Publicado: (2017)

Occurrence of Secondary Malignancies in Chronic Myeloid Leukemia During Therapy with Imatinib Mesylate-Single Institution Experience
por: Helbig, Grzegorz, et al.
Publicado: (2015)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
por: Piccaluga, Pier Paolo, et al.
Publicado: (2012)

Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia
por: Patel, Vihang, et al.
Publicado: (2017)

Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib
por: Maruta, Shunsuke, et al.
Publicado: (2021)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia
por: Arora, Geetika, et al.
Publicado: (2022)

Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
por: Boquimpani, Carla, et al.
Publicado: (2022)

Bone marrow non-mesenchymal mononuclear cells induce functional differentiation of neuroblastoma cells
por: Phruksaniyom, Chareerut, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i6jko1i6frabbvbik7opmhdsbc